

# Belgian National Contact Point for the H2020 MSCA program

**FNRS - MSCA ITN/RISE Info Session**  
**October 5, 2018**



de Duve Institute  
Human Molecular Genetics

Cliniques universitaires St-Luc  
Centre for Vascular Anomalies

Cliniques universitaires St-Luc  
Centre for Human Genetics

copyright © Clin.univ.St-Luc / H. Depasse

**Miikka VIKKULA, MD, PhD**

Professor of Human Genetics,  
Institut de Duve, University of Louvain (UCL) &  
Walloon Excellence in Lifesciences and Biotechnology (WELBIO)  
Brussels, BELGIUM

# Planning

- 1) Plan well ahead: if possible : 3-6 months!**
- 2) Select a cohesive group of beneficiaries**
- 3) Add company/societal partners**
- 4) Administrative issues to all ASAP: PIC # etc.**
- 5) Foresee regular Skype/Webex meetings**
- 6) Ask for input early enough from partners for various Tables**

**7) Read carefully guidelines, and address all in your application.**

**8) Structure for the scientific part is unusual**

**9) Gantt charts etc for interactions**

**10) Secondments of ESRs important  
Plan them logically and well!**

# Content: how to write

## TABLE OF CONTENTS (max. 1 page)

1. EXCELLENCE	5
1.1 Quality, innovative aspects and credibility of the research programme	5
1.1.1 Introduction, objectives and overview of the research programme	6
1.1.2 Research methodology and approach	9
1.1.3 Originality and innovative aspects of the research programme	10
1.2 Quality and innovative aspects of the training programme	11
1.2.1 Overview and content structure of the training	12
1.2.2 Role of non-academic sector in the training programme	15
1.3 Quality of the supervision	16
1.3.1 Qualifications and supervision experience of supervisors	16
1.4 Quality of the proposed interaction between the participating organisations	16
1.4.1 Contribution of all participants to the research and training programme	16
1.4.2 Synergies between participants	17
1.4.3 Exposure of recruited researchers to different (research) environments, and the complementarity thereof	17
2. IMPACT	17
2.1 Enhancing the career perspectives and employability of researchers and contribution to their skills development	18
2.2 Contribution to structuring doctoral research training at the European level and to strengthening European innovation capacity	19
2.2.1 Contribution of the non-academic sector to the doctoral training	19
2.3 Quality of the proposed measures to exploit and disseminate the results	19
2.3.1 Dissemination of research results	19
2.3.2 Exploitation of results and intellectual property	20
2.4 Quality of the proposed measures to communicate the activities to different target audiences	21
2.4.1 Communication and public engagement strategy	21
3. QUALITY AND EFFICIENCY OF THE IMPLEMENTATION	21
3.1 Coherence and effectiveness of the work plan	21
Table 3.1 a Description of Work Packages	21
Table 3.1 b Deliverables List	24
Table 3.1 c - Milestones List	25
Table 3.1 d Individual Research Projects	26
3.2 Appropriateness of the management structures and procedures	30
3.2.1 Network organization and management structure	30
3.2.2 Supervisory Board (SB) and other network bodies	31
3.2.3 Recruitment strategy	32
3.2.4 Progress monitoring and evaluation of individual projects	32
3.2.5 Intellectual Property Rights (IPR) and exploitation management	32
3.2.6 Gender aspects	32
3.2.7 Data Management and Open Access	33
Table 3.2a Implementation Risks	33
3.3 Appropriateness of the infrastructure of the participating organisations	33
3.4 Competences, experience and complementarity of the participating	34

- Why should Europe train young scientists to your area of interest?
- Research should not be isolated (not too academic)
- Benefits to many people/ many Europeans
- Well defined area of interest where there is a need to form young scientist for academia, industry, society
  - \* Not too narrow
  - \* Too large might be difficult for coherence of science
  - \* Detailed description of the learning experience of the students



# RESEARCH & INNOVATION

## Marie Skłodowska-Curie actions

**V.A. Cure**



(V.A. = Vascular Anomalies)

**A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies**

# V.A. Cure : Academic beneficiaries



- most, but not all, knew each other already
  - choose well your beneficiaries
- had 2 very involved beneficiaries to help search partners and to write




# V.A. Cure : Industry beneficiaries

**John WISEMAN**  
ASTRAZENECA  
Mölndal, Sweden

**AstraZeneca**



**Prateek SINGH**  
FINNADVANCE  
Oulu, Finland



**FinnAdvance**





# V.A. Cure partners




## “cutting-edge” technologies

- including next-generation sequencing (including single-cell RNA-Seq)
- CRISPR-Cas genome editing
- generation of animal models with inducible deletion and mosaic analyses
- generation of iPSCs
- microfluidics
- *in vivo* phage display to identify endothelial targets
- light sheet-, confocal-, and multiphoton live-imaging

# Network and Training

	will be used/applied by ESR no													
Key technique/expertise/resource	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Advanced microscopic imaging of cells and tissues (KI)	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Single cell sequencing (KI)						✓	✓							
Analysis of perivascular ECM remodelling (UO)		✓	✓	✓	✓	✓	✓	✓				✓		✓
In vivo phage display technique (AZ)		✓	✓	✓	✓	✓								
TGFb/BMP signalling expertise (INS)					✓		✓	✓					✓	✓
VA patient samples biobank (DDUV)	✓	✓			✓	✓			✓		✓	✓		
Mouse complex vascular phenotyping (UU)		✓	✓	✓					✓					
VA zebrafish models (UP)	✓		✓	✓		✓		✓					✓	
EC metabolism (MPI)			✓	✓							✓	✓		
Microfluidics Platform (FA)	✓					✓	✓	✓					✓	✓
iPSCs (AZ)	✓				✓	✓	✓	✓	✓	✓				
High sensitivity mutation detection in biopsy samples (OB)		✓	✓											
Human EC/mesenchymal stem cell co-culture model (FIC)	✓				✓	✓		✓						


# Scientific work packages (max 4?)



# Secondments : in academia and industry !

ESR	Ac. Exp. 1	Ac. Exp. 2	Ac. Exp. 3	Ind. Exp.1	Ind. Exp. 2
1	DDUV (h)	UO	UP	FA	OB
2	DDUV (h)	UO	UP	FA	OB
3	UP	UU	KI	AZ (h)	
4	UU (h)	UO		OB	
5	UO	UP		AZ (h)	
6	KI (h)	INS	UU	AZ	FA
7	UU (h)	KI	DDUV	FA	
8	UO (h)	DDUV	FIC	FA	
9	UP (h)	MPI	DDUV	LLS	
10	UP (h)	MPI	DDUV	LLS	
11	MPI (h)	DDUV	UU	AZ	
12	INS (h)	UP	UU	AZ	
13	INS (h)	KI	DDUV	FA	
14	KI	INS		FA (h)	

# V.A. Cure Training Programme





**V.A. Cure website - screencast**

**European Researchers' Night**

**Rare Disease Day**


**Patients' day of VASCAPA**

**Press releases and social media announcements**

**Facebook & Twitter:** short descriptions of key findings, images, bullet points (All ESRs responsible )

**Professional help from communication and IT offices of Universities and the companies.**

We used figures, tables and schemes whenever possible



**We have 4 planned workshops (1-2 days each)**

- \* Training of ESRs in various scientific, industrial, and societal aspects**
- \* Reporting on scientific results**
- \* Visits: industry and other partners**


**We do **not** have a hired management company !**

- **Writing on ourselves**
- **Management with existing infrastructures  
(already help from DDUV)**
- **Foresee hiring a project manager**

# V.A. Cure Network:

complementary contributions of all partners to the network.

**8 universities,  
7 companies,  
a hospital and  
a patient  
organisation**



Connection to networks to show that the research is not isolated and will bring benefits to many people.

# Take home messages

---

- 1) Plan well ahead: if possible : 3-6 months!**
- 2) Select a cohesive group of beneficiaries**
- 3) Add company/societal partners**
- 4) Administrative issues to all ASAP: PIC # etc.**
- 5) Foresee regular Skype/Webex meetings**
- 6) Ask for input early enough from partners for various Tables**

# Take home messages

---

**7) Read carefully guidelines, and address all in your application.**

**8) Structure for the scientific part is unusual**

**9) Gantt charts etc for interactions**

**10) Secondments of ESRs important  
Plan them logically and well!**